Derivative works — US Patent 12419895

Defensive Disclosure and Prior Art Publication

Publication Date: May 1, 2026
Publication ID: DPD-2026-12419895-A1
Title: Derivative Methods and Systems for Metabolic Modulation in Subjects with Prader-Willi Syndrome and Analogous Conditions
Inventors/Authors: Gemini Advanced Defensive Research Group
Status: Publicly Disclosed. This document is intended to enter the public domain immediately upon publication to serve as prior art for all subsequent patent applications.

Abstract

This document discloses a plurality of derivative inventions, methods, and systems based on the core teachings of U.S. Patent 12,419,895. The disclosures herein describe novel applications, component substitutions, integrations with emerging technologies, and parameter expansions for the method of treating Prader-Willi Syndrome (PWS) by administering a K-ATP channel opener. These disclosures are intended to render obvious any incremental or foreseeable improvements upon the original invention, thereby dedicating them to the public. The variations described are enabling for a Person Having Ordinary Skill in the Art (POSA).

I. Derivatives Based on the Method of Increasing Lean Body Mass (LBM) in PWS (Relates to Claims 1, 16, 17)

1. Material & Component Substitution

a. Alternative K-ATP Channel Openers

Enabling Description: The method of increasing LBM is achieved by substituting diazoxide with other known K-ATP channel openers. Specifically, minoxidil sulfate, the active metabolite of minoxidil, is formulated for oral administration in a cyclodextrin-based matrix to improve bioavailability. A daily dose of 5 mg to 40 mg is administered to a PWS subject, optionally with standard growth hormone (GH) therapy. The mechanism relies on minoxidil sulfate's potent activation of SUR2B-containing K-ATP channels, which, while distinct from diazoxide's SUR1 preference, also impacts cellular metabolism and nutrient partitioning, leading to a measurable increase in LBM of at least 1% over an 8-week period.

Mermaid Diagram:

graph TD
    A[PWS Subject with Low LBM] --> B{Administer Minoxidil Sulfate};
    B --> C[SUR2B Channel Activation];
    C --> D[Altered Cellular Metabolism];
    D --> E[Preferential Nutrient Partitioning to Muscle];
    E --> F[Increase in LBM >= 1%];

b. Subcutaneous Depot Formulation

Enabling Description: A long-acting injectable (LAI) depot formulation is created using diazoxide suspended in a biodegradable polymer matrix of poly(lactic-co-glycolic acid) (PLGA) with a 75:25 lactide-to-glycolide ratio. The micronized diazoxide particles (1-10 µm) are dispersed within the PLGA solution and injected subcutaneously. The formulation is designed to release a therapeutically effective dose of 1-3 mg/kg/day over a 30-day period. This method avoids first-pass metabolism, provides stable plasma concentrations to reduce side effects, and improves patient compliance, thereby achieving a sustained increase in LBM.

Mermaid Diagram:

classDiagram
    DepotFormulation {
        +PLGA_Matrix
        +Micronized_Diazoxide
        +releaseProfile : String
        +inject()
    }
    PWS_Patient {
        +patientID
        +currentLBM
        +receiveInjection(DepotFormulation)
    }
    Pharmacokinetics {
        +stablePlasmaConcentration
        +avoidFirstPassMetabolism()
    }
    DepotFormulation --|> PWS_Patient : AdministeredTo
    PWS_Patient --|> Pharmacokinetics : Exhibits

2. Operational Parameter Expansion

a. Treatment of Sarcopenic Obesity in Geriatric PWS Subjects

Enabling Description: The method is applied to geriatric PWS subjects (age > 65) who exhibit sarcopenic obesity (co-existence of low LBM and high fat mass). A low-dose regimen of diazoxide (1-2 mg/kg/day) is administered to mitigate age-related decline in insulin sensitivity and preferentially partition nutrients towards muscle tissue. The treatment is continued for a minimum of 6 months. This parameter expansion targets a specific, high-risk sub-population where increasing LBM is critical for maintaining mobility and reducing fracture risk.

Mermaid Diagram:

stateDiagram-v2
    [*] --> GeriatricPWS_Sarcopenic
    GeriatricPWS_Sarcopenic --> LowDoseDiazoxide : Initiate Treatment (1-2 mg/kg/day)
    LowDoseDiazoxide --> NutrientPartitioning : After 4 weeks
    NutrientPartitioning --> LBM_Increase : After 12 weeks
    LBM_Increase --> Mobility_Improvement : After 24 weeks
    Mobility_Improvement --> [*] : Treatment Goal Met

b. Pulsed High-Dose Interventional Therapy

Enabling Description: To overcome metabolic adaptation, a pulsed dosing strategy is employed. A high dose of a K-ATP channel opener (e.g., 8-10 mg/kg/day diazoxide) is administered for a 7-day "induction phase," followed by a 14-day "washout phase" with no drug. This cycle is repeated. The high-dose pulse is designed to induce a significant shift in metabolic flux and gene expression related to myogenesis, while the washout period allows insulin signaling pathways to recover, potentially re-sensitizing the subject for the next pulse and maximizing the anabolic effect on LBM.

Mermaid Diagram:

gantt
    title Pulsed High-Dose Therapy Cycle
    dateFormat  YYYY-MM-DD
    section PWS Patient Treatment
    Induction Phase 1 :active, 2026-05-01, 7d
    Washout Phase 1 :         2026-05-08, 14d
    Induction Phase 2 :active, 2026-05-22, 7d
    Washout Phase 2 :         2026-05-29, 14d

3. Cross-Domain Application

a. AgTech: Increasing Lean Yield in Production Swine

Enabling Description: The core principle of using a K-ATP channel opener to modulate metabolism is applied to animal husbandry. A feed additive containing a stabilized form of nicorandil is provided to finishing swine (e.g., Sus scrofa domesticus) during the final 60 days before slaughter. The dosage is calculated to be 0.5 mg/kg of body weight per day. By activating K-ATP channels in adipose and muscle tissue, the method reduces fat deposition and increases the rate of protein synthesis in skeletal muscle, resulting in a carcass with a higher percentage of lean meat (Loin Eye Area increase of >3%) and improved feed conversion ratio.

Mermaid Diagram:

graph TD
    A[Finishing Swine] --> B[Administer Nicorandil Feed Additive];
    B --> C[Metabolic Shift];
    C --> D[Decrease Lipogenesis];
    C --> E[Increase Myogenesis];
    D & E --> F[Higher Lean Meat % & Improved Feed Conversion];
    F --> G[Increased Economic Value];

b. Aerospace: Mitigating Microgravity-Induced Muscle Atrophy

Enabling Description: A method to counteract muscle atrophy in astronauts during long-duration spaceflight. Astronauts are administered a controlled-release formulation of a K-ATP channel opener (pinacidil, 25 mg/day) starting 14 days prior to launch and continuing for the duration of the mission. Activation of sarcolemmal K-ATP channels is hypothesized to mimic certain aspects of the cellular stress response to exercise, reducing the rate of protein degradation and preserving muscle fiber size and function in a microgravity environment. LBM is monitored using electrical impedance myography.

Mermaid Diagram:

sequenceDiagram
    participant Astronaut
    participant GroundControl
    participant OnboardPharmaSystem
    GroundControl->>OnboardPharmaSystem: Authorize Pinacidil Regimen
    loop Mission Duration
        OnboardPharmaSystem->>Astronaut: Dispense Daily 25mg Dose
        Astronaut->>Astronaut: Ingests Pinacidil
        Note over Astronaut: K-ATP channel activation mitigates protein degradation
    end
    Astronaut->>GroundControl: Transmit LBM data (EIM)

4. Integration with Emerging Tech

a. AI-Driven Personalized Dosing for LBM Optimization

Enabling Description: A closed-loop therapeutic system integrates a wearable bio-impedance sensor (measuring LBM/fat mass), a continuous glucose monitor (CGM), and an AI-powered dosing algorithm. The AI model, trained on PWS-specific metabolic data, analyzes real-time data streams to predict the subject's anabolic response. It then transmits commands to a wirelessly controlled insulin pump, which has been repurposed to deliver micro-doses of a liquid K-ATP channel opener formulation. The system titrates the dose dynamically to maximize the rate of LBM accretion while minimizing hyperglycemia.

Mermaid Diagram:

graph LR
    subgraph Patient
        A(Bio-Impedance Sensor) --> C{AI Core};
        B(CGM) --> C;
    end
    subgraph Cloud
        C -- Analysis --> D[Personalized Dose Calculation];
    end
    subgraph Actuator
        D -- Command --> E(Smart Drug Pump);
        E -- Administer --> F[PWS Subject];
        F -- Feedback --> A & B;
    end

5. The "Inverse" or Failure Mode

a. LBM-Stabilizing Maintenance Therapy

Enabling Description: This method is not designed to increase LBM but to prevent its loss. It is for PWS patients who have achieved a target LBM through GH therapy or other interventions and are at high risk of regression. A very low, sub-therapeutic dose of diazoxide (0.5 mg/kg/day) is administered. This dose is insufficient to cause significant metabolic shifts for LBM gain but is effective in maintaining the metabolic state of the muscle cells, preventing the catabolic drift often seen when primary anabolic therapies are tapered. It functions as a metabolic "lock" to preserve gains.

Mermaid Diagram:

stateDiagram-v2
    state "Target LBM Achieved" as Achieved
    state "LBM Maintenance" as Maintenance
    state "LBM Regression" as Regression

    [*] --> Achieved
    Achieved --> Maintenance : Initiate Low-Dose Diazoxide (0.5 mg/kg/day)
    Maintenance --> Maintenance : LBM Stable
    Maintenance --> Regression : If Therapy Ceases
    Achieved --> Regression : If No Maintenance Therapy

II. Derivatives Based on the Method of Reducing Hyperphagia (Relates to Claim 8)

1. Material & Component Substitution

a. Orexin Receptor Antagonist Co-formulation

Enabling Description: To create a synergistic effect on hyperphagia, a K-ATP channel opener (diazoxide, 3 mg/kg/day) is co-formulated in a bi-layer tablet with a dual orexin receptor antagonist (DORA), such as suvorexant (10 mg). The K-ATP channel opener provides a baseline metabolic signal of energy sufficiency by inhibiting insulin, while the DORA directly suppresses the hypothalamic "wake and seek food" signals mediated by orexin. This dual-pathway inhibition provides a more profound and sustained reduction in hyperphagia (>25% on the Hyperphagia Questionnaire) than either agent alone.

Mermaid Diagram:

graph TD
    subgraph Hypothalamus
        A(Orexin Receptors) -- Blocked by DORA --> B(Reduced Food-Seeking Drive)
    end
    subgraph Pancreas/Metabolism
        C(Pancreatic beta-cells) -- Inhibited by Diazoxide --> D(Reduced Insulin --> Satiety Signal)
    end
    B & D --> E(Synergistic Reduction in Hyperphagia)
    E --> F[PWS Subject];

2. Cross-Domain Application

a. Aquaculture: Appetite Control for Optimized Growth Cycles

Enabling Description: In the farming of carnivorous fish like Atlantic Salmon (Salmo salar), feed is a major cost, and aggressive feeding can lead to waste and poor water quality. This method involves introducing a K-ATP channel opener into the aqueous environment in a controlled, pulsed manner to temporarily suppress appetite. By reducing hyperphagia during specific periods (e.g., post-grading or pre-harvest), farmers can manage growth rates, reduce feed waste, and improve the overall efficiency of the aquaculture operation. The K-ATP opener is cleared from the fish's system well before harvest.

Mermaid Diagram:

gantt
    title Salmon Farming Appetite Control
    dateFormat  MM-DD
    section Growth Cycle
    Normal Feeding      : 05-01, 30d
    Appetite Suppression : 06-01, 5d
    Normal Feeding      : 06-06, 30d
    Pre-Harvest Fasting : 07-06, 3d

3. Integration with Emerging Tech

a. IoT-Monitored Behavioral Intervention

Enabling Description: A system combines a low-dose K-ATP channel opener with an IoT-enabled "smart kitchen." Sensors on refrigerators and pantry doors log all food-access events. A wearable wristband monitors physiological signs of agitation often preceding food-seeking behavior in PWS. When the system's AI detects a pattern of hyperphagic behavior (e.g., frequent, agitated access attempts), it triggers an alert to a caregiver's phone and logs the event against the patient's medication schedule. This data is used to titrate the drug dose to the minimum effective level required to control the specific patient's behavioral patterns.

Mermaid Diagram:

sequenceDiagram
    participant Patient
    participant SmartKitchenSensors
    participant CaregiverAI
    loop Continuous Monitoring
        Patient->>SmartKitchenSensors: Attempts to access food
        SmartKitchenSensors->>CaregiverAI: Log Access Event (Time, Duration)
        alt Hyperphagic Pattern Detected
            CaregiverAI->>CaregiverAI: Correlate with drug schedule
            CaregiverAI->>CaregiverAI: Recommend dose adjustment
        end
    end

III. Combination Prior Art with Open-Source Standards

1. AI-Dosing Algorithm with TensorFlow and FHIR

Enabling Description: A method for personalized treatment of PWS subjects where a predictive model, built using the open-source TensorFlow framework, determines the optimal daily dose of a K-ATP channel opener. The model ingests patient data (genotype, age, weight, LBM, food logs) formatted according to the open FHIR (Fast Healthcare Interoperability Resources) standard. The system's output is a FHIR-compliant MedicationRequest resource, which is transmitted to a pharmacy or clinical management system, ensuring interoperability with existing electronic health records (EHRs). This combination of an open-source AI framework and an open data standard allows for a transparent, reproducible, and integrable clinical decision support tool.

2. Genomic-Stratified Treatment Protocols via ClinVar

Enabling Description: A method wherein PWS subjects are first stratified based on their specific genetic subtype (e.g., Type I Deletion, Type II Deletion, Uniparental Disomy). This genetic information is retrieved from or cross-referenced with the open-source ClinVar database. A treatment algorithm then selects a specific K-ATP channel opener and starting dose based on published associations in ClinVar between the genetic variant and metabolic phenotype. For example, subjects with subtypes linked to more severe insulin dysregulation might receive a higher initial dose. This creates a data-driven, personalized medicine approach based on public, open-source genomic data.

3. Blockchain-Verified Supply Chain for Combination Therapy

Enabling Description: A method for ensuring the authenticity and integrity of the combination therapy (K-ATP channel opener and Growth Hormone). The supply chain is managed on a permissioned blockchain platform built using the open-source Hyperledger Fabric framework. Each drug package is assigned a unique, non-fungible token (NFT). Every transaction—from manufacturer to distributor to pharmacy to patient administration—is recorded as an immutable block. Caregivers can scan a QR code on the package to verify its entire provenance on the blockchain, preventing counterfeiting and ensuring that the two critical components of the therapy are authentic and have been properly handled.